The growth of Theranostics is transforming approaches in treating cancer.

With radiotherapeutics representing 21% of the total radiopharmaceutical market today (with a forecast of 74% by 2031) and 100+ companies with products under development looking to enter nuclear medicine/radiotherapeutics¹, it seems the growth will only continue.

Medhat M. Osman, MD, PhD, ScM

Chair of Nuclear Medicine,
Saint Louis University

How can you prepare for the growth of Theranostics?

Hear Medhat M. Osman, MD, PhD, ScM explain the practical considerations needed in establishing a Theranostics program.

Gain strategy and insight from one of the seven comprehensive radiopharmaceutical therapy centers of excellence already involved in treatments in the United States.

Learn more about our Total MI for Theranostics solutions.

1: MEDRaysintell 2021

© 2022 General Electric Company

GE and the GE Monogram are trademarks of General Electric Company.

Not all products or features are available in all geographies. Check with your local GE Healthcare representative for availability in your country.

JB21061XX